Movement Alert｜Argenx SE Intraday Rise 3.36%, Shares Rebound After Recent Trial Setback

Market Focus10-15

On October 15, Argenx SE rose 3.36% in Regular Trading, trading at $828.15 per share, with turnover of $176 million.

The most recent market-moving development tied to the stock is a rebound following the company’s earlier disclosure that it discontinued the phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjogren’s disease after an independent data monitoring committee found the trial unlikely to meet its primary endpoint.

That setback had pressured the stock on October 8, with reports indicating a pre-market drop of more than 14%. At the same time, Argenx SE also said its phase 2 FB102 study in adults with celiac disease met its primary endpoint, showing a statistically significant and clinically relevant treatment effect versus placebo, with no new safety signals. More recently, the company was also identified among continental European ADR gainers, rising 3.4% in US trading on October 14, consistent with the latest recovery move.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment